CDNA on Nasdaq
CareDx, Inc
Medical transplant company.1
Price unavailable
Last updated Oct 16, 2026.
Overview
Jan 1, 2000Founded1
Compare with CASTLE BIOSCIENCES INC, Fulgent Genetics or BillionToOne (United States), or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Service brought in 72% of the revenue CareDx, Inc broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2023 | 2024 | 2025 |
|---|---|---|---|
| Service | $209.7M | $249.4M | $274.5M |
| Patient And Digital Solutions | $37.1M | $43.6M | $56.9M |
| Product | $33.5M | $40.8M | $48.4M |
Regions
United States brought in 95% of the revenue CareDx, Inc broke down this way in fiscal 2025.
Regions by year
| Regions | 2023 | 2024 | 2025 |
|---|---|---|---|
| United States | $265.6M | $317.7M | $359.9M |
| Outside the United States | $14.7M | $16.1M | $19.9M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Research and development19¢$71.4M
- Other costs81¢$308.1M
- Income tax0¢$271.0K
Out of $379.8M in revenue.4 The company lost money this year.
Where each dollar of operating cash went, fiscal 2025
- Share buybacks100¢$87.8M
Out of $42.0M of cash from operations. Spending exceeded cash from operations; the rest came from savings or borrowing.4
Financial statements
Every line of the income statement in the latest annual report, as filed.4
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Total revenue | $379.8M | $333.8M | $280.3M |
| Research and development | $71.4M | $72.5M | $82.4M |
| Sales and marketing | $102.6M | $82.0M | $84.1M |
| General and administrative | $107.6M | $125.1M | $118.8M |
| Litigation settlement expense | $5.7M | -$96.3M | $96.3M |
| Total operating expenses | $410.6M | $293.0M | $483.7M |
| (Loss) income from operations | -$30.8M | $40.8M | -$203.4M |
| Interest income, net | $9.2M | $11.8M | $11.9M |
| Other income, net | $524.0K | $329.0K | $1.4M |
| Total other income | $9.7M | $12.1M | $13.2M |
| (Loss) income before income taxes | -$21.1M | $52.9M | -$190.1M |
| Income tax expense | -$271.0K | -$310.0K | -$141.0K |
| Net (loss) income | -$21.4M | $52.5M | -$190.3M |
| Basic (in dollars per share) | -$0.40 | $1.00 | -$3.54 |
| Diluted (in dollars per share) | -$0.40 | $0.93 | -$3.54 |
| Basic (in shares) | 53.3M shares | 52.8M shares | 53.8M shares |
| Diluted (in shares) | 53.3M shares | 56.6M shares | 53.8M shares |
Every line of the balance sheet in the latest annual report, as filed.4
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $65.4M | $114.7M | $82.2M |
| Marketable securities | $111.8M | $146.0M | |
| Accounts receivable | $42.6M | $64.6M | |
| Inventory | $26.7M | $19.5M | |
| Prepaid and other current assets | $10.6M | $7.1M | |
| Total current assets | $257.1M | $351.8M | |
| Property and equipment, net | $33.0M | $33.6M | |
| Operating lease right-of-use assets | $22.8M | $24.3M | |
| Marketable securities, non-current | $24.2M | $0 | |
| Intangible assets, net | $32.0M | $38.2M | |
| Goodwill | $40.3M | $40.3M | |
| Restricted cash | $551.0K | $585.0K | $586.0K |
| Other assets | $3.4M | $2.2M | |
| Total assets | $413.2M | $491.1M | |
| Accounts payable | $10.0M | $7.7M | |
| Accrued compensation | $38.1M | $38.3M | |
| Accrued and other liabilities | $41.8M | $43.4M | |
| Total current liabilities | $89.8M | $89.4M | |
| Deferred tax liability | $181.0K | $164.0K | |
| Contingent consideration | $161.0K | $174.0K | |
| Operating lease liabilities, less current portion | $19.7M | $22.3M | |
| Other liabilities | $257.0K | $645.0K | |
| Total liabilities | $110.1M | $112.6M | |
| Preferred stock: $0.001 par value; 10,000,000 shares authorized at December 31, 2025 and 2024; no shares issued and outstanding at December 31, 2025 and 2024 | $0 | $0 | |
| Common stock: $0.001 par value; 100,000,000 shares authorized at December 31, 2025 and 2024; 50,916,644 shares issued and outstanding at December 31, 2025; 54,771,203 shares issued and outstanding at December 31, 2024 | $50.0K | $51.0K | |
| Additional paid-in capital | $1.0B | $1.0B | |
| Accumulated other comprehensive loss | -$5.5M | -$8.6M | |
| Accumulated deficit | -$735.4M | -$626.2M | |
| Total stockholders equity | $303.1M | $378.4M | $261.3M |
| Total liabilities and stockholders equity | $413.2M | $491.1M | |
| Common stock, shares issued (in shares) | 50.9M shares | 54.8M shares | |
| Preferred stock, par value (in dollars per share) | $0.00 | $0.00 | |
| Preferred stock, shares authorized (in shares) | 10.0M shares | 10.0M shares | |
| Preferred stock, shares issued (in shares) | 0 shares | 0 shares | |
| Preferred stock, shares outstanding (in shares) | 0 shares | 0 shares | |
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | |
| Common stock, shares authorized (in shares) | 100.0M shares | 100.0M shares | |
| Common stock, shares outstanding (in shares) | 50.9M shares | 54.8M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.4
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net (loss) income | -$21.4M | $52.5M | -$190.3M |
| Stock-based compensation | $34.9M | $66.4M | $49.1M |
| Asset impairments and write-downs | $0 | $0 | $1.0M |
| Impairment of intangible asset and associated construction in progress | $2.3M | $0 | $0 |
| Depreciation and amortization | $15.0M | $14.2M | $14.4M |
| Amortization of right-of-use assets | $5.4M | $5.6M | $5.4M |
| Realized gain on sale of long-term marketable equity securities, net | $0 | $0 | -$284.0K |
| Loss on disposal of asset | $48.0K | $91.0K | $44.0K |
| Gain on settlement of obligation and recovery of written-off investment | $0 | $0 | -$2.1M |
| Revaluation of common stock warrant liability to estimated fair value | $0 | $0 | -$10.0K |
| Revaluation of contingent consideration to estimated fair value | $703.0K | $931.0K | $2.7M |
| Amortization of premium and accretion of discount on marketable securities, net | $1.3M | $621.0K | -$4.9M |
| Accounts receivable | $22.5M | -$13.7M | $16.0M |
| Inventory | -$5.0M | -$1.0M | $54.0K |
| Prepaid and other assets | -$4.4M | $606.0K | $1.8M |
| Accounts payable | $808.0K | -$5.1M | $2.9M |
| Accrued compensation | -$845.0K | $18.7M | $2.7M |
| Accrued and other liabilities | -$3.3M | -$95.7M | $89.6M |
| Accrued royalties | $0 | $0 | -$1.6M |
| Operating lease liabilities, net | -$6.0M | -$5.9M | -$5.4M |
| Deferred taxes | $17.0K | -$187.0K | $566.0K |
| Net cash provided by (used in) operating activities | $42.0M | $38.0M | -$18.4M |
| Maturities of marketable securities | $154.7M | $166.9M | $256.0M |
| Purchases of marketable securities | -$145.9M | -$160.3M | -$201.2M |
| Purchase of corporate equity securities | $0 | -$634.0K | -$965.0K |
| Sale of corporate equity securities | $0 | $0 | $2.5M |
| Additions of capital expenditures | -$5.9M | -$6.5M | -$8.3M |
| Acquisition of intangible assets | -$675.0K | $0 | -$896.0K |
| Acquisition of business, net of cash acquired | $0 | $0 | -$6.7M |
| Net cash provided by (used in) investing activities | $2.2M | -$483.0K | $40.4M |
| Payment of contingent consideration | -$1.5M | -$5.3M | -$625.0K |
| Repurchase and retirement of common stock | -$87.8M | -$522.0K | -$27.5M |
| Proceeds from exercise of warrants | $0 | $0 | $4.0K |
| Proceeds from exercise of stock options | $5.7M | $8.9M | $120.0K |
| Proceeds from issuance of common stock under employee stock purchase plan | $2.3M | $1.4M | $1.5M |
| Taxes paid related to net share settlement of restricted stock units | -$12.1M | -$10.1M | -$3.1M |
| Net cash used in financing activities | -$93.4M | -$5.6M | -$29.6M |
| Effect of exchange rate changes on cash and cash equivalents | -$90.0K | $532.0K | -$112.0K |
| Net (decrease) increase in cash, cash equivalents and restricted cash | -$49.3M | $32.5M | -$7.7M |
| Cash paid for income taxes | $284.0K | $317.0K | $738.0K |
| Shares issued in lieu of payment | $88.0K | $174.0K | $216.0K |
| Operating lease right-of-use assets | $3.4M | $195.0K | $607.0K |
| Purchases of capital expenditures in accounts payable and accrued liabilities | $3.2M | $633.0K | $647.0K |
| Employee stock purchase plan shares included in accrued compensation | $1.1M | $975.0K | $556.0K |
| Contingent consideration | $0 | $0 | $3.5M |
Former names
Timeline
- Jan 1, 2000Founded Founded1
Recent filings
- Oct 5, 20264
- Oct 5, 20264
- Oct 5, 20264
- Oct 5, 20264
- Oct 5, 20264
- Sep 16, 20268-K/A
- Sep 15, 20264
- Sep 15, 20264
- Aug 17, 2026144
- Aug 14, 2026SCHEDULE 13G/A
- Aug 14, 2026144
- Aug 13, 2026144
- Aug 12, 2026144
- Aug 11, 2026144
- Aug 10, 2026144
Every filing from the last three years, summarized. The full record is on SEC EDGAR.2
Links
- Websitewww.caredx.com1
- WikidataQ106238469
- SEC EDGARCIK 1217234
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1WikidataCareDx, Inc on Wikidata
- 2SEC EDGARCareDx, Inc filings on SEC EDGAR
- 3SEC EDGARCareDx, Inc filings on SEC EDGAR
- 4SEC EDGARCareDx, Inc 10-K for fiscal 2025
- 5SEC EDGARCareDx, Inc 10-K for fiscal 2019
- 6SEC EDGARCareDx, Inc 10-K for fiscal 2020
- 7SEC EDGARCareDx, Inc 10-K for fiscal 2021
- 8SEC EDGARCareDx, Inc 10-K for fiscal 2022
- 9SEC EDGARCareDx, Inc 10-K for fiscal 2019
- 10SEC EDGARCareDx, Inc 10-Q for fiscal 2026
- 11SEC EDGARCareDx, Inc 10-Q for fiscal 2026
- 12SEC EDGARCareDx, Inc 10-K for fiscal 2019